Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextromethorphan is a widely used over-the-counter antitussive (cough suppressant) found in more than 120 cold and cough medications, either alone or in combination with other drugs. It is primarily indicated for the temporary relief of cough caused by the common cold, flu, or other conditions. Dextromethorphan acts on the central nervous system to suppress the cough reflex by decreasing activity in specific areas of the brain that trigger coughing. Mechanistically, it is a nonselective serotonin reuptake inhibitor, a sigma‑1 receptor agonist, and at higher doses acts as an NMDA receptor antagonist via its active metabolite dextrorphan. While structurally related to morphine derivatives (morphinan class), it does not have significant opioid activity at therapeutic doses. In 2022, a combination product containing dextromethorphan and bupropion was approved for major depressive disorder.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextromethorphan.